Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sagarika Basu

Physician Assistant Orlando, FL Physician Assistant

NPI 1174295687 CMS profile 11259671

7485 Sand Lake Commons Blvd, Orlando, FL 32819

Open in the dashboard

General payments

$5,483

214 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sagarika Basu of Orlando, FL is reported in the CMS Open Payments database as having received $5,483 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,568 108
2024 General $1,182 48
2023 General $434 14
2022 General $1,147 39
2021 General $151 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sagarika Basu
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sagarika Basu were reported at $2,568. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sagarika Basu Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $151 $132 $37–$438 $132
2022 $1,147 $155 $48–$522 $149
2023 $434 $167 $52–$557 $160
2024 $1,182 $178 $55–$600 $164
2025 $2,568 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,417 67 payments
  2. Janssen Biotech, Inc. $862 18 payments
  3. Madrigal Pharmaceuticals $718 23 payments
  4. Ardelyx, Inc. $363 16 payments
  5. Phathom Pharmaceuticals, Inc. $280 15 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $275 20 payments
  7. Janssen Scientific Affairs, LLC $248 2 payments
  8. Ironwood Pharmaceuticals, Inc $226 12 payments
  9. Novo Nordisk Inc $222 6 payments
  10. Genzyme Corporation $182 4 payments
  11. Other $688 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,263 211 payments
  2. Education $220 3 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,018 46 payments
  2. TREMFYA $732 14 payments
  3. STELARA $642 11 payments
  4. REZDIFFRA $602 19 payments
  5. SKYRIZI Immunology $555 28 payments
  6. IBSRELA $363 16 payments
  7. SKYRIZI Immunology $320 17 payments
  8. Linzess $226 12 payments
  9. XIFAXAN $222 17 payments
  10. DUPIXENT $182 4 payments
  11. Other $1,896 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

308

Median for Physician Assistant: 241

Drug cost

$7,544

Median for Physician Assistant: $4,110

Branded share of claims

34.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 88 $5,211
Omeprazole Generic 58 $601
Famotidine Generic 43 $525
Pantoprazole Sodium Generic 50 $470
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 19 $260
Dicyclomine Hcl Generic 15 $189
Hydrocortisone Generic 16 $167
Sucralfate Generic 19 $121

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Linzess
  • Ironwood Pharmaceuticals, Inc $189
$189 — —
SKYRIZI
  • AbbVie, Inc. $187
$187 — —
RINVOQ
  • AbbVie, Inc. $185
$185 — —
IBSRELA
  • Ardelyx, Inc. $118
$118 — —
RESMETIROM
  • Madrigal Pharmaceuticals $117
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record